CenExel Clinical Research Acquires ForCare Clinical Research

August 5, 2021

Premier Dermatology Facility in Tampa Bay Joins the CenExel Centers of Excellence 

Salt Lake City, Utah – August 4, 2021 – CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of ForCare Clinical Research (“CenExel FCR”), a Tampa-based clinical research organization with Principal Investigators who have more than 40 years of combined research experience. CenExel FCR conducts Phase I through Phase IV studies in both chronic and acute conditions, primarily in Dermatology.

By acquiring this state-of-the-art facility, CenExel dramatically strengthens its ability to support clinical research in Dermatology and Immunology, as well as several other therapeutic areas. CenExel FCR is led by Principal Investigators who are board certified and conduct studies in Dermatology, Immunology and Inflammatory disease, Neurology, and Internal Medicine.

CenExel FCR will take advantage of the site network’s fully integrated, collaborative processes in centralized budgeting, business development, contracting, SOPs, quality management, among others. CenExel FCR will also work closely with CenExel’s other nine Centers to continue development of Dermatology clinical trials through cross-training and integration.

The CenExel Centers of Excellence network now encompasses ten of the most experienced clinical research facilities in the country, with special emphases in Neurology, Pain, Psychiatry, Vaccines, Dermatology/Immunology, Ethnic-bridging, Sleep studies and Clinical Pharmacology. Each of the CenExel research units have outstanding records of assisting pharmaceutical sponsors with protocol development, study design, and conducting Phase I-IV trials to develop new therapeutics for improved patient care.

“The many strengths at CenExel FCR align perfectly with CenExel’s mission to be the leader in therapeutically focused clinical research. With this addition, CenExel now has the leading plaXorm to conduct clinical trials in Dermatology, CNS, Vaccine, and Clinical Pharmacology,” said Tom Wardle, CenExel CEO. “This addition elevates our entire network. I look forward to working alongside the amazing team at CenExel FCR as we continue to grow together.”

“CenExel FCR will keep exceeding enrollment expecta:ons, preserving subject retention, reducing trial timelines, and delivering reproducible, quality data,” said Misty Sturges, Chief Opera:ng Officer at CenExel FCR. “We’re excited to see even faster study start-up and efficiencies by employing CenExel’s site network resources in our single- and multi-site studies.”

CenExel Clinical Research, Inc. was formed in 2018, and since its formation, CenExel has energetically pursued organic growth as well as the acquisitions of state-of-the-art research centers around the U.S. The mission of CenExel is to work with trial Sponsors and Contract Research Organizations to reduce costs and development times for innovative therapies which may advance patient care. 

Provident Healthcare Partners acted as exclusive sell-side financial advisor to CenExel FCR in the transaction. 

Media Contact: media@CenexelResearch.com